Shionogi Of Japan Begins U.S. Phase II Trials Of Platelet-Deficiency Drug
This article was originally published in PharmAsia News
Executive Summary
Japan's Shionogi says its S-888711 drug to compete with one purchased by Eisai has entered Phase II trials in the United States to treat a deficiency of blood platelets